Clinical Trials Browser

Recruiting × INDUSTRY × Fulvestrant × Clear all

NCT06625775 2026-03-18

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06993844 2026-03-17

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT06997029 2026-03-16

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT07368998 2026-03-16

optINAVO

Phase 2 Recruiting

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

Phase 3 Recruiting

Breast Neoplasms

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07405801 2026-03-09

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06979596 2026-03-06

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06257264 2026-03-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06982521 2026-03-03

ReDiscover-2

Phase 3 Recruiting

Breast Neoplasms

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07109726 2026-02-27

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase 1/2 Recruiting

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07408089 2026-02-24

KOMODO-1

Phase 1 Recruiting

Breast Neoplasms

NCT07288359 2026-02-23

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06998407 2026-02-20

AVZO-023-1001

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

NCT07347600 2026-02-20

reaINAVO

Breast Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05696626 2026-01-26

ELAINEIII

Phase 3 Recruiting

Breast Neoplasms

NCT04115306 2026-01-21

Dauntless-1

Phase 1/2 Recruiting

Breast Neoplasms

NCT06635447 2026-01-13

CAPItrue

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

NCT06726148 2026-01-06

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms

NCT07318805 2026-01-06

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07207070 2025-12-30

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

Breast Neoplasms

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

Breast Neoplasms

NCT06784193 2025-10-10

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

Breast Neoplasms

NCT05735080 2025-09-19

INX-315-01

Phase 1/2 Recruiting

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT04851613 2025-09-16

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

Breast Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT04606446 2025-08-13

KAT6

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06555068 2025-06-22

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Phase 1/2 Recruiting

Breast Neoplasms

NCT06515470 2025-06-06

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT06998108 2025-05-31

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Phase 3 Recruiting

Breast Neoplasms

NCT06954961 2025-05-02

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT04282031 2024-08-07

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Phase 1/2 Recruiting

BreastOther solid neoplasm

Advanced Solid Tumor

NCT04092673 2024-05-21

Zotatifin

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms